Cannabidiol for Canine Osteoarthritis Pain: Mixed Signals From Two Randomized Trials

TL;DR

Recent randomized canine trials of cannabidiol for osteoarthritis pain are mixed: an oral full-spectrum extract showed no significant analgesic benefit over placebo at 90 days, while a long-acting subcutaneous liposomal formulation improved pain and lameness scores in a small crossover pilot. Both reported acceptable short-term safety.

What just dropped

• Griebeler and colleagues (2025) ran a double-blind, randomized trial of a full-spectrum cannabis extract versus placebo in 17 dogs with osteoarthritis over 90 days. The extract did not significantly reduce pain on the Helsinki Chronic Pain Index, though a 2.4-point reduction versus placebo was observed at 90 days, and the treatment was reported as safe with only mild, self-resolving side effects. Source: https://europepmc.org/articles/PMC12682811
• Shilo-Benjamini and colleagues (2025) tested a liposomal synthetic cannabidiol given subcutaneously versus placebo in a randomized, blinded crossover trial in eight dogs with radiographically confirmed osteoarthritis; pain and lameness scores and behavior were significantly improved after treatment compared with placebo. Source: https://europepmc.org/articles/PMC12862949
• In the liposomal study, plasma cannabidiol was detectable for up to four weeks after a single subcutaneous injection, and adverse effects were limited to a couple of days of fever and minor-to-moderate local swelling that resolved spontaneously. Source: https://europepmc.org/articles/PMC12862949

Context

Canine osteoarthritis is common and often incompletely controlled, which has fueled interest in cannabidiol as an adjunct. The two trials illustrate why the evidence remains unsettled: study designs, formulations, and routes differ substantially. The oral full-spectrum extract trial was essentially negative for its primary pain endpoint, while the long-acting injectable pilot was positive but very small, and both were short in duration.

A recurring theme across cannabidiol research, including these osteoarthritis studies, is acceptable short-term tolerability paired with as-yet-uncertain efficacy. Oral cannabidiol also has poor bioavailability due to extensive first-pass hepatic metabolism, which is part of the rationale for the liposomal slow-release approach.

What this changes in canine osteoarthritis pain management

For clinicians fielding owner questions about cannabidiol for arthritic dogs (see the grapiprant evergreen at https://www.thevoyage.ai/forvets/knowledge/grapiprant-canine-osteoarthritis-pain), these trials support a measured message: cannabidiol appears reasonably tolerated over short periods, but a consistent analgesic benefit has not been established, and results may depend heavily on formulation and route. It is not a substitute for evidence-based osteoarthritis analgesics. Any product choice, route, and dosing should be confirmed against a current formulary and the clinician's own judgment, and larger trials are needed.

References

1. Griebeler NM, Cremonese RP, Fakih Correa YR, et al. 2025. Cannabis-based extract for managing pain in dogs with osteoarthritis: efficacy and safety assessment. Front Pharmacol. https://europepmc.org/articles/PMC12682811
2. Shilo-Benjamini Y, Milgram J, Lavy E, et al. 2025. Efficacy, pharmacokinetics and safety of liposomal synthetic cannabidiol injected subcutaneously in dogs: a randomized, blinded, placebo-controlled, crossover clinical trial. Front Vet Sci. https://europepmc.org/articles/PMC12862949

Voyage Clinical Desk

From clinical question to SOAP draft — cited differentials, live dose calculators, owner handouts. Trained on the veterinary canon (Plumb's, Ettinger, JVIM, ACVIM consensus, 50,000+ indexed references). First answer free, no signup.

Open Voyage Clinical Desk: https://www.thevoyage.ai/forvets/ask?context=update-2026-06-20-cannabidiol-canine-osteoarthritis-pain

Related reads

• Grapiprant (Galliprant) for Canine Osteoarthritis Pain: EP4 Antagonism and Clinical Evidence
• Cannabidiol Canine Epilepsy